Radiation for Glioblastoma in the Era of Coronavirus Disease 2019 (COVID-19): Patient Selection and Hypofractionation to Maximize Benefit and Minimize Risk

Sonal S. Noticewala; Ethan B. Ludmir; Andrew J. Bishop; Caroline Chung; Amol J. Ghia; David Grosshans; Susan McGovern; Arnold de la Cruz Paulino; Chenyang Wang; Kristina D. Woodhouse; Debra N. Yeboa; Sujit S. Prabhu; Shiao Pei Weathers; Prajnan Das; Albert C. Koong; Mary Frances McAleer; Jing Li

doi:10.1016/j.adro.2020.04.040

Radiation for Glioblastoma in the Era of Coronavirus Disease 2019 (COVID-19): Patient Selection and Hypofractionation to Maximize Benefit and Minimize Risk

Sonal S. Noticewala, Ethan B. Ludmir, Andrew J. Bishop, Caroline Chung, Amol J. Ghia, David Grosshans, Susan McGovern, Arnold de la Cruz Paulino, Chenyang Wang, Kristina D. Woodhouse, Debra N. Yeboa, Sujit S. Prabhu, Shiao Pei Weathers, Prajnan Das, Albert C. Koong, Mary Frances McAleer, Jing Li

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

We describe the institutional guidelines of a major tertiary cancer center with regard to using hypofractionated radiation regimens to treat glioblastoma as a measure to minimize exposure to coronavirus disease 2019 (COVID-19) while not sacrificing clinical outcomes. Our guidelines review level one evidence of various hypofractionated regimens, and recommend a multidisciplinary approach while balancing the risk of morbidity and mortality among individuals at high risk for severe illness from COVID-19 infection. We also briefly outline strategies our department is taking in mitigating risk among our cancer patients undergoing radiation.

Original language	English (US)
Pages (from-to)	743-745
Number of pages	3
Journal	Advances in Radiation Oncology
Volume	5
Issue number	4
DOIs	https://doi.org/10.1016/j.adro.2020.04.040
State	Published - Jul 1 2020

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging

MD Anderson CCSG core facilities

Clinical Trials Office

Access to Document

10.1016/j.adro.2020.04.040

Cite this

Noticewala, S. S., Ludmir, E. B., Bishop, A. J., Chung, C., Ghia, A. J., Grosshans, D., McGovern, S., Paulino, A. D. L. C., Wang, C., Woodhouse, K. D., Yeboa, D. N., Prabhu, S. S., Weathers, S. P., Das, P., Koong, A. C., McAleer, M. F., & Li, J. (2020). Radiation for Glioblastoma in the Era of Coronavirus Disease 2019 (COVID-19): Patient Selection and Hypofractionation to Maximize Benefit and Minimize Risk. Advances in Radiation Oncology, 5(4), 743-745. https://doi.org/10.1016/j.adro.2020.04.040

Noticewala, SS , Ludmir, EB , Bishop, AJ , Chung, C , Ghia, AJ , Grosshans, D , McGovern, S , Paulino, ADLC , Wang, C, Woodhouse, KD, Yeboa, DN , Prabhu, SS , Weathers, SP , Das, P , Koong, AC , McAleer, MF & Li, J 2020, 'Radiation for Glioblastoma in the Era of Coronavirus Disease 2019 (COVID-19): Patient Selection and Hypofractionation to Maximize Benefit and Minimize Risk', Advances in Radiation Oncology, vol. 5, no. 4, pp. 743-745. https://doi.org/10.1016/j.adro.2020.04.040

@article{8d0112e3e9be4bcd9fc019f4efc4f1d0,

title = "Radiation for Glioblastoma in the Era of Coronavirus Disease 2019 (COVID-19): Patient Selection and Hypofractionation to Maximize Benefit and Minimize Risk",

abstract = "We describe the institutional guidelines of a major tertiary cancer center with regard to using hypofractionated radiation regimens to treat glioblastoma as a measure to minimize exposure to coronavirus disease 2019 (COVID-19) while not sacrificing clinical outcomes. Our guidelines review level one evidence of various hypofractionated regimens, and recommend a multidisciplinary approach while balancing the risk of morbidity and mortality among individuals at high risk for severe illness from COVID-19 infection. We also briefly outline strategies our department is taking in mitigating risk among our cancer patients undergoing radiation.",

author = "Noticewala, {Sonal S.} and Ludmir, {Ethan B.} and Bishop, {Andrew J.} and Caroline Chung and Ghia, {Amol J.} and David Grosshans and Susan McGovern and Paulino, {Arnold de la Cruz} and Chenyang Wang and Woodhouse, {Kristina D.} and Yeboa, {Debra N.} and Prabhu, {Sujit S.} and Weathers, {Shiao Pei} and Prajnan Das and Koong, {Albert C.} and McAleer, {Mary Frances} and Jing Li",

note = "Funding Information: Sources of support: No funding. Disclosures: Dr. Caroline Chung reports research funding from RaySearch Laboratories and Siemens. Dr. Prajnan Das reports honorarium from Adlai Nortye and the MD Anderson Cancer Center in Madrid, Spain. Dr. Albert C. Koong is a stockholder of Aravive, Inc. All other authors have no conflicts of interest to report. Funding Information: Disclosures: Dr. Caroline Chung reports research funding from RaySearch Laboratories and Siemens. Dr. Prajnan Das reports honorarium from Adlai Nortye and the MD Anderson Cancer Center in Madrid, Spain. Dr. Albert C. Koong is a stockholder of Aravive, Inc. All other authors have no conflicts of interest to report. Publisher Copyright: {\textcopyright} 2020 The Author(s)",

year = "2020",

month = jul,

day = "1",

doi = "10.1016/j.adro.2020.04.040",

language = "English (US)",

volume = "5",

pages = "743--745",

journal = "Advances in Radiation Oncology",

issn = "2452-1094",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - Radiation for Glioblastoma in the Era of Coronavirus Disease 2019 (COVID-19)

T2 - Patient Selection and Hypofractionation to Maximize Benefit and Minimize Risk

AU - Noticewala, Sonal S.

AU - Ludmir, Ethan B.

AU - Bishop, Andrew J.

AU - Chung, Caroline

AU - Ghia, Amol J.

AU - Grosshans, David

AU - McGovern, Susan

AU - Paulino, Arnold de la Cruz

AU - Wang, Chenyang

AU - Woodhouse, Kristina D.

AU - Yeboa, Debra N.

AU - Prabhu, Sujit S.

AU - Weathers, Shiao Pei

AU - Das, Prajnan

AU - Koong, Albert C.

AU - McAleer, Mary Frances

AU - Li, Jing

N1 - Funding Information: Sources of support: No funding. Disclosures: Dr. Caroline Chung reports research funding from RaySearch Laboratories and Siemens. Dr. Prajnan Das reports honorarium from Adlai Nortye and the MD Anderson Cancer Center in Madrid, Spain. Dr. Albert C. Koong is a stockholder of Aravive, Inc. All other authors have no conflicts of interest to report. Funding Information: Disclosures: Dr. Caroline Chung reports research funding from RaySearch Laboratories and Siemens. Dr. Prajnan Das reports honorarium from Adlai Nortye and the MD Anderson Cancer Center in Madrid, Spain. Dr. Albert C. Koong is a stockholder of Aravive, Inc. All other authors have no conflicts of interest to report. Publisher Copyright: © 2020 The Author(s)

PY - 2020/7/1

Y1 - 2020/7/1

N2 - We describe the institutional guidelines of a major tertiary cancer center with regard to using hypofractionated radiation regimens to treat glioblastoma as a measure to minimize exposure to coronavirus disease 2019 (COVID-19) while not sacrificing clinical outcomes. Our guidelines review level one evidence of various hypofractionated regimens, and recommend a multidisciplinary approach while balancing the risk of morbidity and mortality among individuals at high risk for severe illness from COVID-19 infection. We also briefly outline strategies our department is taking in mitigating risk among our cancer patients undergoing radiation.

AB - We describe the institutional guidelines of a major tertiary cancer center with regard to using hypofractionated radiation regimens to treat glioblastoma as a measure to minimize exposure to coronavirus disease 2019 (COVID-19) while not sacrificing clinical outcomes. Our guidelines review level one evidence of various hypofractionated regimens, and recommend a multidisciplinary approach while balancing the risk of morbidity and mortality among individuals at high risk for severe illness from COVID-19 infection. We also briefly outline strategies our department is taking in mitigating risk among our cancer patients undergoing radiation.

UR - http://www.scopus.com/inward/record.url?scp=85087175212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85087175212&partnerID=8YFLogxK

U2 - 10.1016/j.adro.2020.04.040

DO - 10.1016/j.adro.2020.04.040

M3 - Article

C2 - 32775785

AN - SCOPUS:85087175212

SN - 2452-1094

VL - 5

SP - 743

EP - 745

JO - Advances in Radiation Oncology

JF - Advances in Radiation Oncology

IS - 4

ER -

Radiation for Glioblastoma in the Era of Coronavirus Disease 2019 (COVID-19): Patient Selection and Hypofractionation to Maximize Benefit and Minimize Risk

Abstract

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Fingerprint

Cite this